secwatch.observer — SEC 8-K summary
======================================

Issuer:     uniQure N.V. (QURE)
CIK:        0001590560
Form:       8-K
Filed at:   2023-02-27T23:59:59+00:00
Accession:  0001104659-23-026119
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

uniQure reports FY2022 net loss of $126.8M; revenue drops to $106.5M from $524M
-------------------------------------------------------------------------------

- Net loss of $126.8M ($2.71 loss per share) vs net income of $329.6M in 2021.
- Revenue of $106.5M, down 80% YoY, primarily due to absence of large license revenue from CSL Behring transaction.
- Cash and investments $392.8M as of Dec 31, 2022; expects funding into 2025 assuming $100M milestone from HEMGENIX first U.S. sale.
- HEMGENIX received U.S. and EU marketing approvals for hemophilia B; eligible for $100M and $75M milestone payments from CSL Behring.
- Pipeline: AMT-130 Huntington's update expected Q2 2023; AMT-162 (SOD1 ALS) and AMT-260 (epilepsy) Phase I/II trials expected H2 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1590560/000110465923026119/0001104659-23-026119-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1590560/000110465923026119/tm237999d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-026119

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer